Publication related to RSI or an RSI staff member

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease.

Authors

  • Crispo, James A G, Crispo JAG, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Human Sciences Division, NOSM University, Sudbury, ON P3E 2C6, Canada.

  • Farhat, Nawal, Farhat N, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

  • Fortin, Yannick, Fortin Y, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

  • Perez-Lloret, Santiago, Perez-Lloret S, Observatorio de Salud, Pontificia Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas (UCA-CONICET), Buenos Aires C1107AAZ, Argentina.; Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires C1121ABG, Argentina.

  • Sikora, Lindsey, Sikora L, Health Sciences Library, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

  • Morgan, Rebecca L, Morgan RL, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada.

  • Habash, Mara, Habash M, Aboriginal Cancer Control Unit, Cancer Care Ontario, Toronto, ON M5G 2L7, Canada.

  • Gogna, Priyanka, Gogna P, Department of Public Health Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.

  • Kelly, Shannon E, Kelly SE, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada.

  • Elliott, Jesse, Elliott J, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

  • Kohen, Dafna E, Kohen DE, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.

  • Bjerre, Lise M, Bjerre LM, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Department of Family Medicine, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Institut du Savoir Montfort, Ottawa, ON K1K 0T2, Canada.

  • Mattison, Donald R, Mattison DR, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Risk Sciences International, Ottawa, ON K1P 5J6, Canada.

  • Hessian, Renee C, Hessian RC, University of Ottawa Heart Institute, University of Ottawa, Ottawa, ON K1Y 4W7, Canada.

  • Willis, Allison W, Willis AW, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Neurology, Translational Center of Excellence for Neuroepidemiology and Neurological Outcomes Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

  • Krewski, Daniel, Krewski D, McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Risk Sciences International, Ottawa, ON K1P 5J6, Canada.

YEAR OF PUBLICATION: 2024
SOURCE: Brain Sci. 2024 Jul 31;14(8):776. doi: 10.3390/brainsci14080776.
JOURNAL TITLE ABBREVIATION: Brain Sci
JOURNAL TITLE: Brain sciences
ISSN: 2076-3425 (Print) 2076-3425 (Electronic) 2076-3425 (Linking)
VOLUME: 14
ISSUE: 8
PLACE OF PUBLICATION: Switzerland
ABSTRACT:
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
LANGUAGE: eng
DATE OF PUBLICATION: 2024 Jul 31
DATE OF ELECTRONIC PUBLICATION: 20240731
DATE REVISED: 20240903
MESH DATE: 2024/08/31 09:52
EDAT: 2024/08/31 09:51
STATUS: PubMed-not-MEDLINE
PUBLICATION STATUS: epublish
LOCATION IDENTIFIER: 10.3390/brainsci14080776 [doi] 776
OWNER: NLM

Related RSI Experts

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski

Donald Mattison

Chief Medical Officer, Senior Vice-President

Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Read More about Donald Mattison